We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S
News

Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S

Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S
News

Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cytori Therapeutics and GE Healthcare announce an agreement by which GE Healthcare will commercialize Cytori’s StemSource® technology in the North American stem cell banking and research markets.

The StemSource technology includes automated equipment to process stem and regenerative cells found in adipose tissue, cryopreserve them or use them directly for research purposes.

In January 2009, Cytori and GE Healthcare formed a separate agreement to commercialize Cytori’s products in ten European countries. This includes selling the Celution® 800/CRS System in the European cosmetic and reconstructive surgery market as well as selling StemSource products in the European cell banking and research markets.

The partnership entered is similar in nature to the European agreement, but is limited to the sale of StemSource banking and research products in the U.S., Canada and Mexico for 18 months starting in the second quarter of 2009. The agreement does not include U.S. commercialization of Cytori’s Celution System, which is currently under review by the FDA.
Advertisement